Nov 16 (Reuters) – The US Food and Drug Administration on Monday approved at-home use of BioXcel Therapeutics’ drug, Igalmi, for agitation associated with schizophrenia or bipolar disorder.
The company last month completed the sale of nearly all its assets, including Igalmi, to a unit of Israel-based Teva Pharmaceuticals.
Here are more details:
• The approval expands Igalmi’s use to outpatient settings without supervision of a healthcare provider, where there are no FDA-approved options available, Teva said
• Teva said it will announce commercialization plans for the drug’s at-home use at a later date
• Igalmi, chemically known as dexmedetomidine, was approved as an orally dissolving film in April 2022 to treat agitation associated with schizophrenia or bipolar disorder in adults with medical supervision
• Schizophrenia is a mental health disorder that causes delusions, hallucinations and disorganized thinking. Bipolar disorder, also a mental health condition, causes strong mood swings
• Agitation associated with schizophrenia and bipolar disorder affects 25% to 40% of patients across these conditions, Teva said
• Igalmi targets brain receptors that help reduce stress-related behaviors such as agitation, a common symptom in patients with neurological disorders that causes physical or mental unease and excessive motor activity
(Reporting by Sneha S K in Bengaluru; Editing by Shreya Biswas)

